drugset
drugset / Trial / NCT00976716

An Open-Label Study Of Celecoxib In Patients With Posttraumatic Pain

NCT00976716 ↗

Phase 3 Completed 80 enrolled Viatris Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To investigate efficacy, safety and tolerability of Celecoxib in patients with posttraumatic pain for the duration of 8 days.

Timeline

Start
2009-09
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 200 mg —

Indications

No indication recorded.